2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2600

Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial
Abstract Number: 2567

Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-Naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results through Week 24 from a Phase 3 Study
Abstract Number: 2464

Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis
Abstract Number: 770

Cognitive Function Trajectories Are Associated with the Depressive Symptoms Trajectories in SLE over Time
Abstract Number: 782

Cognitive Impairment and Health-Related Quality of Life in a Lupus Cohort
Abstract Number: 487

Cognitive Impairment in Rheumatoid Arthritis Patients: A Case-Control Study
Abstract Number: 491

Cognitive Impairment Is Associated with Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 1956

Cohort Effects in Back Pain: The Effect of Changes in Life-Style and Co-Occurring Conditions
Abstract Number: 1649

Cohort Identification of Axial Spondyloarthritis in a Large Healthcare Dataset: Current and Future Methods
Abstract Number: 2277

Colchicine: An Effective Treatment Option for Unclassified Autoinflammatory Diseases in Children
Abstract Number: 70

Colocalization of Malondialdehyde-Acetaldehyde Adducts (MAA) and Extracellular Matrix Proteins in Joint and Lung Tissues from Rheumatoid Arthritis Patients
Abstract Number: 596

Combination of Intra-Articular Steroid Injection and Tofacitinib More Effective Than Tofacitinib in Rapid Radiographic Progression Patients with Rheumatoid Arthritis
Abstract Number: 1329

Combination of Methotrexate and Leflunomide in Refractory Chronic Adult Onset Still’s Disease: Case Series and Literature Review
Abstract Number: 1452

Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis
Abstract Number: 60

Combined Inhibition of Mechanistic Target of Rapamycin and Glutamine Metabolism Inhibits CD4 T Cell Proliferation and Th17 Differentiation, Facilitates the Expansion of Myeloid-Derived Suppressor Cells, and Synergistically Ameliorates Arthritis in SKG Mice

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].